A Phase I Study with Neratinib (HKI-272), an Irreversible...

Clinical Cancer Research 2009 / 03 Vol. 15; Iss. 7

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Wong, K.-K., Fracasso, P. M., Bukowski, R. M., Lynch, T. J., Munster, P. N., Shapiro, G. I., Janne, P. A., Eder, J. P., Naughton, M. J., Ellis, M. J., Jones, S. F., Mekhail, T., Zacharchuk, C., Vermet
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
15
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-08-1978
Date:
March, 2009
File:
PDF, 214 KB
english, 2009
Conversion to is in progress
Conversion to is failed